Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.
about
Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditisDouble-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicityHigh risk of cross-reactivity between vancomycin and sequential teicoplanin therapy.Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patientsTeicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureusBactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.Impact of infectious diseases consultation on the management of Staphylococcus aureus bacteraemia in childrenStaphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection modelProtein binding and serum bactericidal activities of vancomycin and teicoplanin.Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers.Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patientsAssessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic modelDaptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplaninRandomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters.Teicoplanin in the treatment of gram-positive-bacterial endocarditis.Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocciCurrent perspectives on glycopeptide resistance.Pharmacokinetics of teicoplanin in renal failureProtein binding of vancomycin in a patient with immunoglobulin A myeloma.Methicillin-resistant staphylococci: detection methods and treatment of infections.Beta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureus.Impact of routine bedside infectious disease consultation on clinical management and outcome of Staphylococcus aureus bacteraemia in adultsMethicillin-resistant staphylococci.Resistance to vancomycin and teicoplanin: an emerging clinical problem.Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium.Effect of protein binding of daptomycin on MIC and antibacterial activity.Teicoplanin in perspective. A critical comparison with vancomycin.Therapeutic update on glycopeptide and lipopeptide antibiotics.Rapid identification of methicillin-resistant Staphylococcus aureus from positive blood cultures by real-time fluorescence PCRRole of pharmacokinetics in the outcome of infections.Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin.Association of Evidence-Based Care Processes With Mortality in Staphylococcus aureus Bacteremia at Veterans Health Administration Hospitals, 2003-2014.Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.
P2860
Q24645282-C01F5C16-D6E2-42C7-8DC4-07EA76D4D067Q28326763-37AA9B1F-4CED-4D89-9200-1A9C84E2633EQ33397749-D7F12FDB-555E-491F-BAD6-837F4AB8FBA9Q33742289-B26993AA-5155-4BE8-8F46-DE5836D7C46FQ33756241-D56F341D-CB7F-4932-BCCF-42FC3CEB0FBEQ33758399-56B6D264-1060-4431-9C44-6B35AA27BC21Q33758447-956F57D0-6189-48F7-97C5-DFE5E5D90EE9Q33879578-89C26BA5-1924-4953-89A8-B9EAECE6E903Q34478074-7CD5A629-5B04-4C89-87AF-F77312879D32Q35117243-677028BD-4CCE-40D3-9671-4C8C81857C12Q35117545-F31D9C09-0A78-4816-B7B9-99E7243A8313Q35243618-99053947-E001-4263-A0A9-3DA9AB3BB4BAQ35251599-5A603E39-0F19-4DD1-9C0D-9BF5D6036C22Q35271608-FADD7755-9BF0-42F7-A08E-410513B90E58Q35276965-58C6DB57-2290-4F8B-A3D3-755A3BED5226Q35280233-714F5AA3-6E8F-4D2F-B8C4-FAF388E5392BQ35285763-5E8A9F8E-1A10-4B58-8609-84FB53C00139Q35341106-A8281E09-4B78-4E0E-BA43-11D2F5AD8A45Q35344121-8034C784-274A-4F19-9F77-19150BEBEA6FQ35361659-C083F753-F20C-4F0C-A9B1-ACF4395A9980Q35368590-B1E76901-FE7B-49F5-A154-C8AA576CF384Q35541154-8D4E5856-6E79-4424-A846-D83914A96BCCQ35565490-A68643F0-458B-4BD8-836A-D2BC6657CD0AQ35566190-C09660C9-0567-4965-A27B-B6AB32B87209Q35820407-B8E9D3DC-69BF-41BD-899F-0F3FB65C94C5Q35875149-1C3933A2-9B77-4B61-9ACD-769E5D9A0871Q36632851-449DC496-2FA1-406D-84BD-708B3F90E2F8Q36636341-D4C96DD9-9AF9-4C68-A668-1FC11C3BB845Q36752580-8000F72F-2D0E-4410-995E-BD9D251814F5Q36753066-070A44E4-3F13-4DD8-9A21-449D2B8AA61DQ36754480-764E41B3-0E16-47A8-8722-07CA666117DBQ36757414-A48E28C4-E49D-44DE-B30D-F1BC1A32BE63Q37113420-65309352-7FDE-4260-9ECE-1C22411B9709Q39291062-04753097-379F-4A55-BCBB-5640BF90F1C5Q39467428-E3DA553D-45DF-4E51-9072-2A86B29D9D15Q39639407-9C01DD03-BCBC-4E63-9198-89A147DD2C42Q39815862-BC763382-612B-4BA0-B3F0-30BDF45D598DQ39815914-5C3CFADE-863B-465C-8841-CCDCD3AB096CQ40066467-105B6E7E-F1F5-456E-9EF4-BA6DCC393715Q40087244-D4730D9A-D8C9-476E-A892-4BBAC8E842E3
P2860
Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Early termination of a prospec ...... ere staphylococcal infections.
@en
type
label
Early termination of a prospec ...... ere staphylococcal infections.
@en
prefLabel
Early termination of a prospec ...... ere staphylococcal infections.
@en
P2093
P356
P1476
Early termination of a prospec ...... ere staphylococcal infections.
@en
P2093
Auckenthaler R
Hirschel B
Waldvogel F
P304
P356
10.1093/INFDIS/155.2.187
P407
P577
1987-02-01T00:00:00Z